4SC AG: Preliminary announcement of the publication of financial reports according to Articles 37v, 37w, 37y of the WpHG [the German Securities Act]
December 19, 2017 at 07:40 am EST
Share
DGAP Preliminary announcement financial reports: 4SC AG / Preliminary announcement on the disclosure of financial statements
4SC AG: Preliminary announcement of the publication of financial reports according to Articles 37v, 37w, 37y of the WpHG [the German Securities Act]
19.12.2017 / 13:34
Preliminary announcement of the publication of financial reports according to Articles 37v, 37w, 37y of the WpHG [the German Securities Act] transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
4SC AG hereby announces that the following financial reports shall be
disclosed :
Report: Financial report (half-year/Q2)
Date of disclosure / German: August 09, 2018
Date of disclosure / English: August 09, 2018
German: https://www.4sc.de/investoren/investoren-informationen/finanzberichte/
English: http://www.4sc.com/investors/investor-information/financial-reports/
Report: Annual financial report of the group
Date of disclosure / German: March 28, 2018
Date of disclosure / English: March 28, 2018
German: https://www.4sc.de/investoren/investoren-informationen/finanzberichte/
English: http://www.4sc.com/investors/investor-information/financial-reports/
19.12.2017 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Companyâs product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
4SC AG 
